Professor Matthias Trost

by | 22 Jul 2022 | Newcastle, Supervisors | 0 comments

Matthias TrostEmail:

Research profile and key clinical specialties

My group utilises primarily proteomics (but also many other techniques) to answer important biological and medical questions.

Our primary biological research interests are in innate immunity (macrophages/neutrophils), bacterial infection and innate immune signalling.

We further have substantial research interests in drug discovery, including high-throughput approaches and identification of target and off-targets of drugs and characterising their mode of action.

Two key publications

  • Miettinen, T.P., Peltier, J., Härtlova, A., Gierliński, M., Jansen, V.M., Trost, M.* and Björklund*, M., Thermal profiling of breast cancer cells identifies the proteasome as a target for CDK4/6 inhibitor palbociclib, EMBO Journal (2018), May 15;37(10). pii: e98359. doi: 10.15252/embj.201798359 (*corresponding authors)
  • Härtlova, A., Herbst, S., Peltier, J., Rodgers, A., Bilkei-Gorzo, O., Fearns, A., Dill, B.D., Lee, H., Flynn, R., Cowley, S.A., Davies, P., Lewis, P., Ganley, I.G., Martinez, J., Alessi, D.R., Reith, A.D., Trost, M.*, Gutierrez, M.G.*, The Parkinson’s disease kinase LRRK2 is a negative regulator of phagosome maturation and innate immunity to tuberculosis in macrophages, EMBO Journal (2018), May 22. pii: e98694. doi: 10.15252/embj.201798694 (*corresponding authors)

Possible PhD projects

  • Proteomics characterisation of patient samples (tissue preferred over plasma) in a relevant disease area.
  • Drug discovery in patient samples.
  • Identifying mode of action or off-targets of drugs.

More information

Good success with (non-clinical) fellowships. Well-funded lab (Wellcome Trust, UKRI, EU). Ongoing collaborations with GSK and Boehringer Ingelheim. Member of BBSRC and MRC panels.

Keywords: Proteomics, macrophages, neutrophils, drug, discovery, Matthias, Trost, Newcastle